| scholarly article | Q13442814 |
| P50 | author | John D Hainsworth | Q73567269 |
| P2093 | author name string | William M Merritt | |
| Dana S Thompson | |||
| Victor G Gian | |||
| B Stephens Dudley | |||
| Robert C Whorf | |||
| John A Bismayer | |||
| Lindsey H Finney | |||
| P2860 | cites work | Nonparametric Estimation from Incomplete Observations | Q25938997 |
| New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 | ||
| Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study | Q28258045 | ||
| BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis | Q29617585 | ||
| Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial | Q30429122 | ||
| Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study | Q33348987 | ||
| Carboplatin dosage: prospective evaluation of a simple formula based on renal function | Q33429552 | ||
| The prognostic significance of angiogenesis in epithelial ovarian carcinoma. | Q33547562 | ||
| Molecular and biological properties of vascular endothelial growth factor | Q33737216 | ||
| A phase 3 trial of bevacizumab in ovarian cancer | Q34030022 | ||
| Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer | Q37474070 | ||
| Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer | Q39576387 | ||
| Sorafenib in Combination With Gemcitabine in Recurrent Epithelial Ovarian Cancer: A Study of the Princess Margaret Hospital Phase II Consortium | Q42905241 | ||
| Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer. | Q43142299 | ||
| Incorporation of bevacizumab in the primary treatment of ovarian cancer | Q44579933 | ||
| A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma. | Q51065459 | ||
| A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. | Q53298171 | ||
| Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer. | Q54523915 | ||
| Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. | Q54566293 | ||
| Prognostic and predictive value of tumour angiogenesis in ovarian carcinomas | Q71195247 | ||
| Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup | Q74339084 | ||
| Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial | Q87460208 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ovarian cancer | Q172341 |
| P304 | page(s) | 673-681 | |
| P577 | publication date | 2014-12-31 | |
| P1433 | published in | Cancer Medicine | Q27724564 |
| P1476 | title | Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research Institute | |
| P478 | volume | 4 |
| Q38631373 | An overview of tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer. |
| Q58706801 | Antiangiogenesis therapy in ovarian cancer patients: An updated meta-analysis for 15 randomized controlled trials |
| Q92548235 | Assessment of Progression-Free Survival as a Surrogate End Point of Overall Survival in First-Line Treatment of Ovarian Cancer: A Systematic Review and Meta-analysis |
| Q33662162 | Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review |
| Q57456582 | Cardiovascular Toxicities with Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer Patients: A Meta-Analysis of 77 Randomized Controlled Trials |
| Q91906673 | Chemotherapy Resistance in Advanced Ovarian Cancer Patients |
| Q38813996 | Clinical outcome of treatment with serine-threonine kinase inhibitors in recurrent epithelial ovarian cancer: a systematic review of literature. |
| Q36696710 | Comparative Proteomic Analysis of Advanced Ovarian Cancer Tissue to Identify Potential Biomarkers of Responders and Nonresponders to First-Line Chemotherapy of Carboplatin and Paclitaxel |
| Q92697428 | Comparative efficacy of targeted maintenance therapy for newly diagnosed epithelial ovarian cancer: a network meta-analysis |
| Q38751236 | Current and emerging treatment options in the management of advanced ovarian cancer |
| Q38735349 | Epithelial-to-Mesenchymal Transition in Paclitaxel-Resistant Ovarian Cancer Cells Is Downregulated by Luteolin |
| Q28079328 | Incidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patients |
| Q31138109 | Is ovarian cancer a targetable disease? A systematic review and meta-analysis and genomic data investigation |
| Q97544423 | Natural compound Tan-I enhances the efficacy of Paclitaxel chemotherapy in ovarian cancer |
| Q28082524 | New perspectives on targeted therapy in ovarian cancer |
| Q26777846 | Ovarian Cancer Molecular Stratification and Tumor Heterogeneity: A Necessity and a Challenge |
| Q37570010 | Platelet Derived Growth Factor BB: A "Must-have" Therapeutic Target "Redivivus" in Ovarian Cancer. |
| Q56957787 | Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial |
| Q55476332 | Stomatitis and VEGFR-Tyrosine Kinase Inhibitors (VR-TKIs): A Review of Current Literature in 4369 Patients. |
| Q59796299 | Synergistic Activity of Paclitaxel, Sorafenib, and Radiation Therapy in advanced Renal Cell Carcinoma and Breast Cancer |
| Q98164379 | Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence |
| Q26824766 | Targeting angiogenesis in gynecologic cancers |
| Q50345037 | The rise of genomic profiling in ovarian cancer |
| Q64062159 | Therapeutic Targeting of Collective Invasion in Ovarian Cancer |
| Q33770035 | Therapeutic strategies for targeting the ovarian tumor stroma |
| Q47344306 | Transporter-Mediated Interaction Between Platinum Drugs and Sorafenib at the Cellular Level |
Search more.